MA44699A - Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer - Google Patents

Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer

Info

Publication number
MA44699A
MA44699A MA044699A MA44699A MA44699A MA 44699 A MA44699 A MA 44699A MA 044699 A MA044699 A MA 044699A MA 44699 A MA44699 A MA 44699A MA 44699 A MA44699 A MA 44699A
Authority
MA
Morocco
Prior art keywords
antagonist
oligonucleotide
cancer
treatment
combination
Prior art date
Application number
MA044699A
Other languages
English (en)
Inventor
Robert L Coffman
Andrew Evan Denker
Cristiana Guiducci
Robert S Janssen
Robert A Kastelein
David Ross Kaufman
Uyen Truong Phan
Svetlana Sadekova
Ying Yu
Original Assignee
Merck Sharp & Dohme
Surefire Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Surefire Medical Inc filed Critical Merck Sharp & Dohme
Publication of MA44699A publication Critical patent/MA44699A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA044699A 2015-05-29 2016-05-26 Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer MA44699A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562168449P 2015-05-29 2015-05-29
US201562169309P 2015-06-01 2015-06-01

Publications (1)

Publication Number Publication Date
MA44699A true MA44699A (fr) 2021-05-05

Family

ID=57441888

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044699A MA44699A (fr) 2015-05-29 2016-05-26 Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer

Country Status (13)

Country Link
US (2) US10751412B2 (fr)
EP (2) EP3892284B1 (fr)
JP (2) JP6893608B2 (fr)
KR (1) KR20180014009A (fr)
CN (1) CN108025018B (fr)
AU (1) AU2016271018A1 (fr)
BR (1) BR112017025562A2 (fr)
CA (1) CA2986126A1 (fr)
ES (1) ES2985394T3 (fr)
MA (1) MA44699A (fr)
MX (1) MX2017015308A (fr)
RU (1) RU2017145558A (fr)
WO (1) WO2016196173A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2014159662A1 (fr) 2013-03-13 2014-10-02 University Of Miami Procédé pour isoler et purifier les microvésicules de surnageants de culture cellulaire et fluides biologiques
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
JP6991857B2 (ja) * 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
PL3240801T3 (pl) * 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
KR20180014009A (ko) 2015-05-29 2018-02-07 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018039629A2 (fr) 2016-08-25 2018-03-01 Northwestern University Acides nucléiques sphériques micellaires obtenus à partir de matrices thermosensibles sans trace
MX2019002925A (es) 2016-09-15 2019-09-05 Idera Pharmaceuticals Inc Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
AR111432A1 (es) 2017-04-28 2019-07-10 Merck Sharp & Dohme Biomarcadores para agentes terapéuticos contra el cáncer
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
WO2018209270A1 (fr) 2017-05-11 2018-11-15 Northwestern University Thérapie cellulaire adoptive utilisant des acides nucléiques sphériques (sna)
MX2020003395A (es) 2017-10-13 2020-08-03 Merck Sharp & Dohme Composiciones y metodos para tratar linfoma difuso de celulas b grandes.
AU2018355519A1 (en) 2017-10-27 2020-03-26 Amgen Inc. Compositions and methods for treating liver cancer
WO2019160866A2 (fr) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions et méthodes d'immunothérapie anti-tumorale
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
WO2019200238A1 (fr) * 2018-04-14 2019-10-17 Dynavax Technologies Corporation Combinaisons comprenant un oligonucléotide de type cpg-c et un inhibiteur d'histone désacétylase pour le traitement du cancer
WO2020081398A1 (fr) * 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combinaison comprenant un oligonucléotide de type cpg-c et un antagoniste de pd-1 pour le traitement du cancer du sein
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (fr) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC Co-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
US20220010008A1 (en) * 2018-12-12 2022-01-13 Shanghai Pharmaexplorer Co., Ltd. Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
CN111321159B (zh) * 2018-12-14 2023-12-12 中天(上海)生物科技有限公司 用于免疫调节的嵌合核酸分子及其应用
TWI833056B (zh) 2019-12-31 2024-02-21 財團法人工業技術研究院 核酸藥物複合體以及其用途
IL294621A (en) * 2020-01-10 2022-09-01 Sbi Biotech Co Ltd Tlr9 agonist oligonucleotides, compositions comprising same and uses thereof
EP4185331A4 (fr) * 2020-07-24 2025-02-26 The Board of Trustees of the Leland Stanford Junior University Vaccin à trois constituants contre la covid-19
CN116685330A (zh) * 2020-09-22 2023-09-01 特萨乐斯生命科学公司 使用toll样受体激动剂的癌症疗法
CA3196273A1 (fr) * 2020-09-22 2022-03-31 Trisalus Life Sciences, Inc. Therapie anticancereuse faisant intervenir des agonistes de recepteurs de type toll
US20230374523A1 (en) * 2020-09-22 2023-11-23 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists
WO2022110010A1 (fr) * 2020-11-27 2022-06-02 苏州吉玛基因股份有限公司 Utilisation d'un activateur immunitaire, d'un antigène et d'un anticorps dans la préparation d'un produit pour la prévention et le traitement de tumeurs
JP2024512765A (ja) * 2021-04-01 2024-03-19 トリサルース・ライフ・サイエンシズ・インコーポレイテッド トール様受容体アゴニストを使用したがん治療
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20250009731A1 (en) 2021-11-08 2025-01-09 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds
US20240180952A1 (en) * 2022-01-11 2024-06-06 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
WO2025233224A1 (fr) 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Utilisation d'inhibiteurs d'atr en combinaison avec une thérapie anti-pd(l)1

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
CA2244946C (fr) 1996-01-30 2010-04-13 The Regents Of The University Of California Vecteurs d'expression genique generant une reponse immune specifique d'un antigene et leurs procedes d'utilisation
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
EP1003850B1 (fr) 1997-06-06 2009-05-27 The Regents of the University of California Inhibiteurs de l'activite de sequences immunostimulatrices de l'adn
JP4663113B2 (ja) 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
EP1176966B1 (fr) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Un oligodesoxynucleotide et son emploi pour induire une reponse immunitaire
KR100881923B1 (ko) 2000-12-27 2009-02-04 다이나박스 테크놀로지 코퍼레이션 면역자극 폴리뉴클레오티드 및 그것의 사용 방법
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
JP5102959B2 (ja) 2002-12-23 2012-12-19 ダイナバックス テクノロジーズ コーポレイション 免疫刺激配列オリゴヌクレオチド及びその使用方法
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
BR122017025062B8 (pt) * 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
EP3255060A1 (fr) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
ES3000111T3 (en) * 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
WO2011066342A2 (fr) 2009-11-24 2011-06-03 Amplimmune, Inc. Inhibition simultanée de pd-l1/pd-l2
WO2012006634A2 (fr) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Thérapie peptidique par antigène prostatique spécifique (psa)
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
MX368257B (es) * 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
RU2689760C2 (ru) * 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US20160084839A1 (en) * 2013-04-02 2016-03-24 Marisa Dolled-Filhart Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
AU2014296887A1 (en) * 2013-08-02 2016-01-28 Aduro Biotech Holdings, Europe B.V. Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
MX2016004570A (es) 2013-10-11 2016-09-08 Genentech Inc Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
US10278984B2 (en) 2014-05-02 2019-05-07 Nitor Therapeutics Guanosine as an immune potentiator mediated through toll receptors
JP6991857B2 (ja) * 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
PL3240801T3 (pl) 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
KR20180014009A (ko) 2015-05-29 2018-02-07 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
MX2017015311A (es) 2015-05-29 2018-06-19 Merck Sharp & Dohme Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.

Also Published As

Publication number Publication date
KR20180014009A (ko) 2018-02-07
EP3892284B1 (fr) 2024-05-22
BR112017025562A2 (pt) 2018-08-07
ES2985394T3 (es) 2024-11-05
JP6893608B2 (ja) 2021-06-23
US11918648B2 (en) 2024-03-05
CN108025018A (zh) 2018-05-11
US20180169229A1 (en) 2018-06-21
EP3302501A4 (fr) 2019-02-27
EP3302501B1 (fr) 2021-09-22
MX2017015308A (es) 2018-07-06
US20210196819A1 (en) 2021-07-01
US10751412B2 (en) 2020-08-25
WO2016196173A1 (fr) 2016-12-08
JP2018516911A (ja) 2018-06-28
EP3892284A1 (fr) 2021-10-13
EP3302501A1 (fr) 2018-04-11
CA2986126A1 (fr) 2016-12-08
AU2016271018A1 (en) 2017-11-30
HK1252652A1 (zh) 2019-05-31
JP7236483B2 (ja) 2023-03-09
JP2021102627A (ja) 2021-07-15
RU2017145558A (ru) 2019-07-01
CN108025018B (zh) 2021-08-17

Similar Documents

Publication Publication Date Title
MA44699A (fr) Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
MA41555A (fr) Polythérapie pour le traitement du cancer
EP3317274A4 (fr) Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3359192A4 (fr) Polythérapie pour le traitement du cancer
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
EP3481393A4 (fr) Association d'un antagoniste de pd-1 et d'un inhibiteur du raf pour le traitement du cancer.
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3331510A4 (fr) Thérapies combinatoires pour le traitement du cancer
EP3302554A4 (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
EP3370725A4 (fr) Dosage pédiatrique pour le traitement du cancer avec un inhibiteur d'ezh2
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer